Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jul;95(29):e4272.
doi: 10.1097/MD.0000000000004272.

Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis

Kamini Devi Boodhoo et al. Medicine (Baltimore). 2016 Jul.

Abstract

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disorder of unknown etiology. It affects both men and women, but with different disease manifestations of differing disease severity and in varying proportion, with a female predominance of approximately 90%. There have been numerous studies addressing this issue, especially its implications in relation to optimal sex-tailored treatment and improvement of survival rate; however, further research is warranted. A meta-analysis of studies was performed to compare the impact of sex on the clinical outcomes of SLE in different populations.

Methods: A literature search of the MEDLINE/PubMed and EMBASE databases (until January 2016) was conducted to identify relevant articles. Clinical manifestations reported in these patients were considered as endpoints for this meta-analysis. Two independent reviewers determined eligibility criteria. A fixed-effect model has been used where a small heterogeneity was observed, or else, a random-effect model has been used among the studies. Odd ratio (OR) with 95% confidence interval (CI) was used to express the pooled effect on dichotomous variables, and the pooled analyses were performed with RevMan 5.3.

Results: Sixteen studies consisting of a total of 11,934 SLE patients (10,331 females and 1603 males) have been included in this meta-analysis. The average female-to-male ratio of all the included studies is around 9.3:1. Several statistically significant differences were found: alopecia, photosensitivity, and oral ulcers were significantly higher in female patients (OR 0.36, 95% CI 0.29-0.46, P < 0.00001; OR 0.72, 95% CI 0.63-0.83, P < 0.00001; and OR 0.70, 95% CI 0.60-0.82, P < 0.00001, respectively). Malar rash was significantly higher in female patients (OR 0.68, 95% CI 0.53-0.88, P = 0.003), and arthritis was significantly lower in male patients (OR 0.72, 95% CI 1.25-1.84, P < 0.00001). However, serositis and pleurisies were significantly higher in female patients (OR 1.52, 95% CI 1.25-1.84 P < 0.0001; and OR 1.26, 95% CI 1.07-1.48, P = 0.006, respectively). Renal involvement was higher in male patients (OR 1.51, 95% CI 1.31-1.75, P < 0.00001).

Conclusion: The results of this meta-analysis suggest that alopecia, photosensitivity, oral ulcers, arthritis, malar rash, lupus anticoagulant level, and low level of C3 were significantly higher in female lupus patients, whereas renal involvement, serositis and pleurisies, thrombocytopenia, and anti-double stranded deoxyribonucleic acid level were predominant in male patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the study selection.
Figure 2
Figure 2
Alopecia, photosensitivity, oral ulcers.
Figure 3
Figure 3
Arthritis, serositis, pleurisies, cardiovascular disease (CVD).
Figure 4
Figure 4
Pericarditis, renal involvement, seizure, psychosis.
Figure 5
Figure 5
Hematological manifestations, hemolytic anemia, lymphopenia.
Figure 6
Figure 6
Malar rash, discoid rash, Raynaud phenomenon, neurological.
Figure 7
Figure 7
Leukopenia, anti-Sm antibodies, anticardiolipin antibodies.
Figure 8
Figure 8
ANA, anti-dsDNA, lupus anticoagulant, low level of C3, low C4 level.
Figure 9
Figure 9
All clinical endpoints in male and female patients with lupus.

Similar articles

Cited by

References

    1. Hopkinson N. Epidemiology of systemic lupus erythematosus. Ann Rheum Dis 1992; 51:1292–1294. - PMC - PubMed
    1. Manzi S. Epidemiology of systemic lupus erythematosus. Am J Manag Care 2001; 7 (16 Suppl):S474–S479. - PubMed
    1. Lu LJ, Wallace DJ, Ishimori ML, et al. Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119–129. - PMC - PubMed
    1. Stefanidou S, Benos A, Galanopoulou V, et al. Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male: female comparison. Lupus 2011; 20:1090–1094. - PubMed
    1. Borba EF, Araujo DB, Bonfa E, et al. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus 2013; 22:744–749. - PubMed